Aligos Therapeutics, Inc. financial data

Symbol
ALGS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
One Corporate Dr., 2 Nd Floor, South San Francisco, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 463 % +1.86%
Debt-to-equity 70.6 % +88.8%
Return On Equity -144 % -93.5%
Return On Assets -84.5 % -55.8%
Operating Margin -1.28 K %

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 75.7 M shares +76.2%
Entity Public Float 20.2 M USD -42.6%
Common Stock, Value, Issued 7 K USD +75%
Weighted Average Number of Shares Outstanding, Basic 156 M shares +264%
Weighted Average Number of Shares Outstanding, Diluted 156 M shares +264%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 6.75 M USD +396%
Research and Development Expense 71.3 M USD -0.37%
General and Administrative Expense 28.8 M USD +1.1%
Operating Income (Loss) -86.3 M USD -0.37%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -98.8 M USD -18.6%
Income Tax Expense (Benefit) 780 K USD +748%
Net Income (Loss) Attributable to Parent -99.6 M USD -19.4%
Earnings Per Share, Basic -1.05 USD/shares +45.9%
Earnings Per Share, Diluted -1.05 USD/shares +45.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 24.2 M USD -69.3%
Cash, Cash Equivalents, and Short-term Investments 113 M USD +8.89%
Other Assets, Current 5.11 M USD -7.38%
Assets, Current 118 M USD +7.89%
Property, Plant and Equipment, Net 3.05 M USD -30.3%
Operating Lease, Right-of-Use Asset 6.17 M USD -15.6%
Other Assets, Noncurrent 625 K USD -1.11%
Assets 128 M USD +5.06%
Accounts Payable, Current 2.84 M USD +0.71%
Employee-related Liabilities, Current 3.06 M USD -0.88%
Accrued Liabilities, Current 12 M USD -20.1%
Liabilities, Current 18.9 M USD -32.8%
Operating Lease, Liability, Noncurrent 6.99 M USD -18.8%
Other Liabilities, Noncurrent 133 K USD -50.2%
Liabilities 68.1 M USD +84.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 476 K USD -4.61%
Retained Earnings (Accumulated Deficit) -522 M USD -23.6%
Stockholders' Equity Attributable to Parent 59.8 M USD -29.4%
Liabilities and Equity 128 M USD +5.06%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.7 M USD -1.6%
Net Cash Provided by (Used in) Financing Activities -19 K USD -1800%
Net Cash Provided by (Used in) Investing Activities -88.6 M USD -543%
Common Stock, Shares Authorized 320 M shares 0%
Common Stock, Shares, Issued 75.7 M shares +76.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 24.4 M USD -69.2%
Deferred Tax Assets, Valuation Allowance 34.2 M USD -68.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 36.6 M USD -67.5%
Operating Lease, Liability 10.9 M USD -10.9%
Depreciation 1.39 M USD -33.4%
Payments to Acquire Property, Plant, and Equipment 19 K USD -98%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -99.6 M USD -19.9%
Lessee, Operating Lease, Liability, to be Paid 12.6 M USD -14.8%
Property, Plant and Equipment, Gross 14.5 M USD +0.45%
Operating Lease, Liability, Current 3.27 M USD +7.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.68 M USD +11.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.56 M USD +4%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure -11.1%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.75 M USD -33.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.8 M USD +11.2%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) 795 K USD +650%
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 99 K USD -96.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.44 M USD -59.2%
Operating Lease, Payments 3.6 M USD +5.88%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 2.38 M USD -25%
Share-based Payment Arrangement, Expense 2.65 M USD -27.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%